Inpharma 1255 - 16 Sep 2000

■ The doxorubicin prodrug HMR-1826* showscomparable antitumour activity to doxorubicin andliposomal doxorubicin in mice bearing human cancercells, report researchers from the US. In this study,athymic nude mice bearing human colon, breast,prostate, renal or pancreatic cancer cells received IVHMR-1826, liposomal doxorubicin [‘Doxil’] ordoxorubicin, or remained as controls (untreated oradministered vehicle only). The 3 active treatmentshad similar activity, except in mice bearing breastcancer cells, where HMR-1826 and liposomaldoxorubicin had greater activity than doxorubicin. Theresearchers note that HMR-1826 tended to produceless drug-induced bodyweight loss than the otheractive treatments.* Aventis Pharma; preclinical

Woesssner R, et al. Comparison of three approaches to doxorubicin therapy:free doxorubicin, liposomal doxorubicin, and beta-glucuronidase-activatedprodrug (HMR 1826). Anticancer Research 20: 2289-2296, Jul-Aug2000 800841883

1

Inpharma 16 Sep 2000 No. 12551173-8324/10/1255-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved